Is PNTG a good stock to buy right now?

Based on our 6-factor quantitative model, Pennant Group, Inc. (PNTG) receives a "Hold" rating with a composite score of 49.3/100. It is ranked #995 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 58/100, Momentum 57/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for PNTG?

Pennant Group, Inc. (PNTG) has a "Hold" rating and 3-star score. The composite score of 49.3 ranks it #995 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is PNTG in?

Pennant Group, Inc. operates in the Healthcare sector (Healthcare industry) with a market cap of $1.05 billion. It is classified as a small-cap stock.

Does PNTG pay a dividend?

PNTG does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is PNTG's P/E ratio?

PNTG has a trailing P/E ratio of 35.82x. The Healthcare sector average is 23.6x. This above-average P/E reflects growth expectations or premium valuation.

How profitable is PNTG?

PNTG's quality factor score is 50/100. Gross margin: 19.0%. ROE: 8.0% vs sector average -43.5%. Margins are moderate to low, reflecting competitive market dynamics.

How is PNTG valued compared to peers?

PNTG's value factor score is 58/100 (higher = cheaper). Key multiples: P/E 35.8x, EV/EBITDA 23.5x. Valuation is roughly in line with peers.

What is PNTG's debt level?

PNTG's debt-to-equity ratio is 45%. Sector average: 32%. Low leverage suggests conservative financial management.

PNTG has a beta of 0.57, meaning it is less volatile than the market. Stability score: 73/100.

Does PNTG have high short interest?

PNTG's short interest factor score is 19/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

PNTG Stock Analysis: Top Small-Cap Hold (Score 49.3/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
PNTG	-3.13%	+3.44%	-9.90%	+8.99%	+22.43%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-3.06%	-0.16%	-10.23%	+9.35%	-7.10%	-	-	-
Alpha vs Sector	-1.77%	+3.10%	-6.08%	+13.83%	+13.22%	-	-	-

Metric	PNTG	Benchmark
P/E Ratio	35.8x	+52%
EV/EBITDA	23.5x	+271%
Price / Book	2.9x

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018
Gross Margin %	0.2%	-	0.2%	-	-	-	0.2%	0.1%	0.1%
Operating Margin %	0.1%	0.1%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%
EBITDA Margin %	0.1%	0.1%	0.1%	0.1%	0.0%	0.0%	0.1%	0.0%	0.1%
Net Margin %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%
FCF Margin %	-6.4%	-	4.4%	-	-	-	11.0%	0.8%	6.9%
ROE %	0.1%	0.1%	0.1%	0.1%	0.1%	0.0%	0.2%	0.0%	0.3%
ROA %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.2%
ROIC %	0.1%	7.5%	11.2%	9.5%	5.3%	2.2%	14.3%	5.0%	29.2%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

Gross Margin %

0.2%

0.1%

Operating Margin %

0.1%

0.0%

0.1%

EBITDA Margin %

0.1%

0.0%

0.1%

0.0%

0.1%

Net Margin %

0.0%

0.1%

FCF Margin %

-6.4%

4.4%

11.0%

0.8%

6.9%

ROE %

0.1%

0.0%

0.2%

0.0%

0.3%

ROA %

0.0%

0.2%

ROIC %

0.1%

7.5%

11.2%

9.5%

5.3%

2.2%

14.3%

5.0%

29.2%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018
	$839M	$948M	$695M	$545M	$473M	$440M	$391M	$339M	$286M
	—	—	$137M	—	—	—	$55M	$80M	$74M
Gross Margin	19.0%	---	19.7%	---	---	---	24.1%	13.2%	14.8%
	—	$71M	—	$37M	—	—	—	—	—
Depreciation	—	$9M	$7M	$5M	$5M	$5M	$5M	$4M	$3M
Total Operating Expenses	—	$896M	—	$520M	$461M	$435M	—	—	—
	$45M	$52M	$38M	$25M	$13M	$5M	$19M	$6M	$21M
EBIT	$45M	$52M	$38M	$25M	$13M	$5M	$19M	$6M	$21M
EBITDA	$53M	$60M	$46M	$30M	$18M	$9M	$24M	$10M	$24M
Operating Margin	5.4%	5.5%	5.5%	4.6%	2.7%	1.1%	4.8%	1.7%	7.2%
EBITDA Margin	6.3%	6.4%	6.5%	5.6%	3.7%	2.2%	6.2%	2.8%	8.2%
	—	—	$7M	$6M	$4M	$2M	$1M	—	—
	—	$46M	—	$20M	$9M	$3M	—	—	—
Income Tax Expense	—	$12M	$7M	$6M	$2M	$582K	$2M	$2M	$4M
	$30M	$34M	$24M	$14M	$7M	$2M	$16M	$3M	$16M
Net Margin	3.6%	3.6%	3.5%	2.5%	1.5%	0.5%	4.0%	0.9%	5.7%
	$0.86	$0.86	$0.72	$0.45	$0.23	$0.09	$0.56	$0.11	$0.58
Diluted EPS	$0.86	$0.84	$0.72	$0.44	$0.22	$0.09	$0.56	$0.11	$0.58
Weighted Avg Basic	—	35M	—	30M	29M	28M	—	—	—
Weighted Avg Diluted	—	35M	—	30M	30M	31M	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

$839M

$948M

$695M

$545M

$473M

$440M

$391M

$339M

$286M

—

$137M

—

$55M

$80M

$74M

Gross Margin

19.0%

---

19.7%

---

24.1%

13.2%

14.8%

—

$71M

—

$37M

—

Depreciation

—

$9M

$7M

$5M

$4M

$3M

Total Operating Expenses

—

$896M

—

$520M

$461M

$435M

—

$45M

$52M

$38M

$25M

$13M

$5M

$19M

$6M

$21M

EBIT

$45M

$52M

$38M

$25M

$13M

$5M

$19M

$6M

$21M

EBITDA

$53M

$60M

$46M

$30M

$18M

$9M

$24M

$10M

$24M

Operating Margin

5.4%

5.5%

4.6%

2.7%

1.1%

4.8%

1.7%

7.2%

EBITDA Margin

6.3%

6.4%

6.5%

5.6%

3.7%

2.2%

6.2%

2.8%

8.2%

—

$7M

$6M

$4M

$2M

$1M

—

$46M

—

$20M

$9M

$3M

—

Income Tax Expense

—

$12M

$7M

$6M

$2M

$582K

$2M

$4M

$30M

$34M

$24M

$14M

$7M

$2M

$16M

$3M

$16M

Net Margin

3.6%

3.5%

2.5%

1.5%

0.5%

4.0%

0.9%

5.7%

$0.86

$0.72

$0.45

$0.23

$0.09

$0.56

$0.11

$0.58

Diluted EPS

$0.86

$0.84

$0.72

$0.44

$0.22

$0.09

$0.56

$0.11

$0.58

Weighted Avg Basic

—

35M

—

30M

29M

28M

—

Weighted Avg Diluted

—

35M

—

30M

31M

—

Pennant Group, Inc. (PNTG) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does Pennant Group, Inc. Do?

The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors, who are independent or who require some support. As of December 31, 2021, the company operated 88 home health and hospice agencies, and 54 senior living communities with 4127 Senior Living units in Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The Pennant Group, Inc. was incorporated in 2019 and is headquartered in Eagle, Idaho. Pennant Group, Inc. (PNTG) is classified as a small-cap stock in the Healthcare sector. The company is led by CEO Brent Guerisoli and employs approximately 5,340 people. With a market capitalization of $1.1B, PNTG is one of the notable companies in the Healthcare sector.

Pennant Group, Inc. (PNTG) Stock Rating — Hold (April 2026)

As of April 2026, Pennant Group, Inc. receives a Hold rating with a composite score of 49.3/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.PNTG ranks #995 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Pennant Group, Inc. ranks among stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

PNTG Stock Price and 52-Week Range

Pennant Group, Inc. (PNTG) currently trades at $30.68. The stock lost $0.99 (3.1%) in the most recent trading session. The 52-week high for PNTG is $34.74, which means the stock is currently trading -11.7% from its annual peak. The 52-week low is $21.73, putting the stock 41.2% above its annual trough. Recent trading volume was 142K shares, suggesting relatively thin trading activity.

Is PNTG Overvalued or Undervalued? — Valuation Analysis

Pennant Group, Inc. (PNTG) carries a value factor score of 58/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 35.82x, compared to the Healthcare sector average of 23.63x — a premium of 52%. The price-to-book ratio stands at 2.88x, versus the sector average of 2.75x. The price-to-sales ratio is 1.28x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, PNTG trades at 23.54x EV/EBITDA, versus 6.34x for the sector.

Overall, PNTG's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

Pennant Group, Inc. Profitability — ROE, Margins, and Quality Score

Pennant Group, Inc. (PNTG) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 8.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 3.1% versus the sector average of -33.1%.

On a margin basis, Pennant Group, Inc. reports gross margins of 19.0%, compared to 71.5% for the sector. The operating margin is 5.4% (sector: -66.1%). Net profit margin stands at 3.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 35.7% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

PNTG Debt, Balance Sheet, and Financial Health

Pennant Group, Inc. has a debt-to-equity ratio of 45.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 1.14x, suggesting adequate working capital coverage. Total debt on the balance sheet is $169M. Cash and equivalents stand at $2M.

PNTG has a beta of 0.57, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Pennant Group, Inc. is 73/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.

Pennant Group, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Pennant Group, Inc. reported revenue of $839M and earnings per share (EPS) of $0.86. Net income for the quarter was $30M. Gross margin was 19.0%. Operating income came in at $45M.

In FY 2025, Pennant Group, Inc. reported revenue of $948M and earnings per share (EPS) of $0.86. Net income for the quarter was $34M. Revenue grew 36.3% year-over-year compared to FY 2024. Operating income came in at $52M.

In Q3 2025, Pennant Group, Inc. reported revenue of $229M and earnings per share (EPS) of $0.18. Net income for the quarter was $7M. Revenue grew 26.8% year-over-year compared to Q3 2024. Operating income came in at $10M.

In Q2 2025, Pennant Group, Inc. reported revenue of $220M and earnings per share (EPS) of $0.21. Net income for the quarter was $8M. Revenue grew 30.1% year-over-year compared to Q2 2024. Operating income came in at $12M.

Over the past 8 quarters, Pennant Group, Inc. has demonstrated a growth trajectory, with revenue expanding from $169M to $839M. Investors analyzing PNTG stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

PNTG Dividend Yield and Income Analysis

Pennant Group, Inc. (PNTG) does not currently pay a dividend. This is common among smaller companies in the Healthcare industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

PNTG Momentum and Technical Analysis Profile

Pennant Group, Inc. (PNTG) has a momentum factor score of 57/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 23/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 19/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

PNTG vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Pennant Group, Inc. (PNTG) ranks #— out of 838 stocks based on the Blank Capital composite score. This places PNTG in the top decile of all Healthcare stocks in our coverage universe.

Comparing PNTG against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PNTG vs S&P 500 (SPY) comparison to assess how Pennant Group, Inc. stacks up against the broader market across all factor dimensions.

PNTG Next Earnings Date

No upcoming earnings date has been announced for Pennant Group, Inc. (PNTG) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy PNTG? — Investment Thesis Summary

Pennant Group, Inc. presents a balanced picture with arguments on both sides. Low volatility (stability score 73/100) reduces downside risk.

In summary, Pennant Group, Inc. (PNTG) earns a Hold rating with a composite score of 49.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PNTG stock.

Related Resources for PNTG Investors

Explore more research and tools: PNTG vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

JPMorgan Chase & Co. Has $3.30 Million Stock Holdings in The Pennant Group, Inc. $PNTG

Pennant Group acquires Mesa senior living facility for $undisclosed By Investing.com

Tudor Investment Corp ET AL Buys 157,574 Shares of The Pennant Group, Inc. $PNTG

The Pennant Group, Inc. (NASDAQ:PNTG) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Pennant Group outlines 22% revenue growth target for 2026 while focusing on integration and operational excellence

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Pennant Group, Inc. (PNTG) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does Pennant Group, Inc. Do?

Pennant Group, Inc. (PNTG) Stock Rating — Hold (April 2026)

PNTG Stock Price and 52-Week Range

Is PNTG Overvalued or Undervalued? — Valuation Analysis

Pennant Group, Inc. Profitability — ROE, Margins, and Quality Score

PNTG Debt, Balance Sheet, and Financial Health

Pennant Group, Inc. Revenue and Earnings History — Quarterly Trend

PNTG Dividend Yield and Income Analysis

PNTG Momentum and Technical Analysis Profile

PNTG vs Competitors — Healthcare Sector Ranking and Peer Comparison

PNTG Next Earnings Date

Should You Buy PNTG? — Investment Thesis Summary

Related Resources for PNTG Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

JPMorgan Chase & Co. Has $3.30 Million Stock Holdings in The Pennant Group, Inc. $PNTG

Pennant Group acquires Mesa senior living facility for $undisclosed By Investing.com

Tudor Investment Corp ET AL Buys 157,574 Shares of The Pennant Group, Inc. $PNTG

The Pennant Group, Inc. (NASDAQ:PNTG) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Pennant Group outlines 22% revenue growth target for 2026 while focusing on integration and operational excellence